Floatz logo

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE

Anxiety Disorder

Hannover Medical SchoolSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Anxiety Disorder cohort.

Asset / SponsorPhaseRating
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 4BBB
Risperidone
Tianjin Medical University General Hospital
Phase 4BBB
Olanzapine
Tianjin Medical University General Hospital
Phase 4BBB
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Theresa Jacob, PhD, MPH
Phase 4BBB
Fluoxetine
Hannover Medical School
Phase 4BBB

View all 50 →

Same molecule, other indications

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE is also rated in:

central nervous system disorderDormant
B
Indicative · Phase 4
62 / 100
View asset →
schizophreniaDormant
B
Indicative · Phase 4
59 / 100
View asset →
physiological malfunction arising from mental factorDormant
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →